Restablecimiento de los efectos antitumorales de la terapia hormonal en cáncer de mama receptor de estrógenos negativo.
Efectos del calcitriol en la regulación de citocinas proinflamatorias en células de cáncer de mama.
Efecto de los antiestrógenos en la expresión de Musashi en cáncer de mama.

Publicaciones

1. Santos-Martínez N, Díaz L, Ortiz-Ortega VM, Ordaz-Rosado D, Prado-Garcia H, Avila E, Larrea F, García-Becerra R. (corresponding author) Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells. Am J Cancer Res, 11(12): 5951-5964. 2021. FI: 6.1
2. Segovia-Mendoza M, García-Quiroz J, Díaz L, García-Becerra R. (corresponding author) Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update. Int. J. Mol. Sci, 22(12741): 1-36. 2021. FI: 5.9.
3. García-Quiroz J, Cárdenas-Ochoa N, García-Becerra R, Morales-Guadarrama G, Méndez-Pérez EA, Santos-Cuevas C, Ramírez-Nava GJ, Segovia-Mendoza M, Prado-García H, Avila E, Larrea F, Díaz L. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro. J Steroid Biochem Mol Biol, 214(105979): 1-11. 2021. FI: 4.2
4. Morales-Guadarrama G, García-Becerra R, Méndez-Pérez EA, García-Quiroz J, Avila E, Díaz L. Vasculogenic mimicry in breast cancer: Clinical relevance and drivers. Cells 10(1758): 1-17. 2021. FI: 6.6
5. Hernández-Borja F, Mercado-Sánchez I, Alcaraz Y, García-Revilla MA, Villegas-Gómez C, Ordaz-Rosado D, Santos-Martínez N, García-Becerra R, Vazquez MA. Exploring novel capping framework: high substituent pyridine hydroxamic acid derivatives as potential antiproliferative agents. DARU J Pharm Sci 2: 291-310. 2021. FI: 3.1
6. Lara‐Sotelo G, Díaz L, García‐Becerra R, Avila E, Prado‐Garcia H, Morales‐Guadarrama G, Ibarra‐Sánchez MJ, Esparza‐López J, Larrea F, García‐Quiroz G. α‐Mangostin synergizes the antineoplastic effects of 5‐fluorouracil allowing a significant dose reduction in breast cancer cells. Processes, 9(458): 1-14. 2021. FI: 2.8
7. García-Olivares M, Romero-Córdoba S, Ortíz-Sánchez E, García-Becerra R, Segovia-Mendoza M, Rangel-Escareño C, Halhali A, Larrea F, Barrera D. Regulation of anti-tumorigenic pathways by the combinatory treatment of calcitriol and TGF-β in PC-3 and DU145 cells. J Steroid Biochem Mol Biol, 209(105831): 1-15. 2021. FI: 4.2
8. García S, Mercado-Sánchez I, Bahena L, Alcaraz Y, García-Revilla MA, Robles J, Santos-Martínez N, Ordaz-Rosado D, García-Becerra R, Vazquez MA. Design of fluorescent coumarin-hydroxamic acid derivatives as inhibitors of HDACs: Synthesis, anti-proliferative evaluation and docking studies. Molecules 25(5134): 1-27. 2020. FI: 4.4
9. Segovia-Mendoza M, Camacho-Camacho C, Rojas-Oviedo I, Prado-Garcia H, Barrera D, Martínez-Reza I, Larrea F, García-Becerra R. (corresponding author) An organotin indomethacin derivative inhibits cancer cell proliferation and synergizes the antiproliferative effects of lapatinib in breast cancer cells. Am J Cancer Res 10(10):3358-3369. 2020. FI: 6.1
10. Segovia-Mendoza M, Gómez de León CT, García-Becerra R, Ambrosio J, Nava-Castro KE, Morales-Montor J. The chemical environmental pollutants BPA and BPS induce alterations of the proteomic profile of different phenotypes of human breast cancer cells: a proposed interactome. Environ Res 191: 1-12. 2020. FI: 6.4
11. García-Quiroz J, García-Becerra R, Santos-Cuevas C, Ramírez-Nava GJ, Morales-Guadarrama G, Cárdenas-Ochoa N, Segovia-Mendoza M, Prado-Garcia H, Ordaz-Rosado D, Avila E, Olmos-Ortiz A, López-Cisneros S, Larrea F, Díaz L. Synergistic antitumorigenic activity of calcitriol with curcumin or resveratrol is mediated by angiogenesis inhibition in triple negative breast cancer xenografts. Cancers 11(1739):1-22. 2019. FI: 6.6
12. Martínez-Reza I, Díaz L, Barrera D, Segovia-Mendoza M, Pedraza-Sánchez S, Soca-Chafre G, Larrea F, García-Becerra R. (corresponding author) Calcitriol inhibits the proliferation of triple negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1β and TNF-α. Journal of Immunology Research 2019:1-11. 2019. FI: 4.8
13. García-Quiroz J, González-González MA, Díaz D, Ordaz-Rosado D, Segovia-Mendoza M, Prado-Garcia H, Larrea F, García-Becerra R. (corresponding author) Astemizole, an inhibitor of ether-à-go-go-1 potassium channel, increases the activity of the tyrosine kinase inhibitor gefitinib in breast cancer cells. Rev Invest Clin 71(3):186-194. 2019 FI: 1.4
14. Olmos-Ortiz A, García-Quiroz J, Halhali A, Avila E, Zaga-Clavellina V, Chavira-Ramírez R, García-Becerra R, Caldiño-Soto F, Larrea F, and Díaz L. Negative correlation between testosterone and TNF-α in umbilical cord serum favors a weakened immune milieu in the human male fetoplacental unit. J Steroid Biochem Mol Biol 186:154–160. 2019 FI: 4.2
15. Lira-Albarrán S, Durand M, Barrera D, Vega C, García-Becerra R, Díaz L, García-Quiroz J, Rangel C, Larrea F. A single preovulatory administration of ulipristal acetate affects the decidualization process of the human endometrium during the receptive period of the menstrual cycle. Mol Cell Endocrinol 15: 476:70-78. 2018. FI: 4.1
16. Martinez-Archundia M, García-Vázquez JB, Colin-Astudillo B, Bello M, Prestegui-Martel B, Chavez A, Dueñas-González A, Fragoso-Vázquez MJ, Mendieta-Wejebe J, Abarca-Rojano E, Ordaz-Rosado D, García-Becerra R, Castillo-Bautista D, and Correa Basurto J. Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand. Anticancer Agents Med Chem 18(11):1508-1520 2018. FI: 2.5
17. Martínez-Reza I, Díaz L, and García-Becerra R. (corresponding author) Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci 24(90): 1-8. 2017. FI: 8.4
18. Escudero-Castellanos A, Ocampo-García BE, Ferro-Flores G, Isaac-Olivé K, Santos-Cuevas CL, Olmos-Ortiz A, García-Quiroz J, García-Becerra R, and Díaz L. Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical. J Radioanal Nucl Chem 2017. FI: 1.3
19. Segovia-Mendoza M, Díaz L, Prado-Garcia H, Reginato MJ, Larrea F, and García-Becerra R. (corresponding author) The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells. Am J Cancer Res 7(7): 1486-1500. 2017. FI: 6.1
20. García-Quiroz J, García-Becerra R, Lara-Sotelo G, Avila E, López S, Santos-Martínez N, Halhali A, Ordaz-Rosado D, Barrera D, Olmos-Ortiz A, Ibarra-Sánchez MJ, Esparza-López J, Larrea F, and Díaz L. Chronic moderate ethanol intake differentially regulates vitamin D hydroxylases gene expression in kidneys and xenografted breast cancer cells in female mice. J Steroid Biochem Mol Biol 173: 148-156. 2017. FI: 4.2

Circuito de Posgrado, Ciudad Universitaria
Alcaldía Coyoacán, C.P. 04510, México, CDMX

55 5623 7006
mdcbq@posgrado.unam.mx